0000950170-25-099652
SEC filingIPO and private placement netted $206M; warrant liabilities extinguished; $246M in investments; $3.8M deferred revenue.
As of June 30, 2025, Beta Bionics held $35.1 million in cash and cash equivalents, $214.6 million in short-term investments (U.S. Treasury bills), and $31.1 million in long-term investments (U.S. Treasury notes), for a total liquidity of $280.9 million. This compares to $30.4 million in cash and $73.1 million in short-term investments at December 31, 2024. The increase was driven by net proceeds of $190.4 million from the IPO and $15.6 million from a private placement, both completed in January 2025. The company has no debt. Total assets were $330.0 million, up from $149.6 million. Stockholders' equity swung from a deficit of $245.4 million to positive $301.6 million, primarily due to the conversion of $321.4 million of convertible preferred stock and $57.3 million of warrant liabilities into common stock. The company's net loss for the six months was $45.5 million.
The Notes disclose a $5.1 million commitment under a clinical supply arrangement with Xeris for phase 3 development and manufacturing costs. As of June 30, 2025, the first payment of $1.5 million had been made. Additionally, the company has operating lease obligations totaling $8.3 million in future payments, with a weighted-average remaining lease term of 6.0 years. The product warranty liability stood at $2.1 million, up from $0.7 million at year-end 2024, reflecting increased sales. Deferred revenue, representing performance obligations for software updates and mobile app access, was $3.8 million, of which $1.1 million is expected to be recognized within 12 months.
The company did not repurchase any shares or pay dividends. Capital expenditures were $2.1 million for the six months, primarily for manufacturing equipment and construction in progress. There was no debt issuance or repayment. The company's primary capital allocation activity was the deployment of IPO proceeds into short- and long-term U.S. Treasury securities.
The company operates as a single operating segment. All revenues are generated in the United States. The Notes provide a disaggregation of revenue by channel: for the six months ended June 30, 2025, $32.5 million (79.4%) came from the DME channel and $8.4 million (20.6%) from the PBP channel. Within the DME channel, iLet sales were $23.0 million and single-use products were $9.4 million. Within the PBP channel, iLet sales were $0.7 million and single-use products were $7.7 million.
For the six months ended June 30, 2025, Beta Bionics reported a net loss of $45.5 million, significantly wider than the $26.9 million loss in the prior period. Cash used in operating activities was $33.6 million, compared to $24.4 million in the prior year. The primary drivers of the operating cash outflow were the net loss and non-cash adjustments including stock-based compensation ($7.6 million) and change in fair value of warrant liabilities ($12.5 million). Working capital changes consumed cash, notably inventory build ($4.4 million) and prepaid expenses ($3.6 million), partially offset by deferred revenue ($1.0 million) and accounts receivable collections ($0.6 million).
Capital expenditures (capex) totaled $2.1 million, up from $0.9 million, indicating increased investment in property and equipment. The investing cash flow was heavily negative at -$172.9 million due to net purchases of short- and long-term investments ($170.8 million net after maturities), largely funded by financing activities.
Financing activities provided $211.2 million, primarily from a public common stock offering ($195.4 million) and a private placement ($15.6 million), along with option exercises. This financing activity more than covered the operating and investing cash outflows, resulting in a net increase in cash of $4.6 million. The company ended the period with $35.2 million in cash and cash equivalents.
Overall, the cash flow statement reflects a company in a growth phase, burning cash from operations while investing heavily in investments and capital assets, relying on equity issuance for funding. The absence of free cash flow (not reported) and no capital returns (dividends or buybacks) underlines the company's focus on funding growth.